Search Orphan Drug Designations and Approvals
-
| Generic Name: | furmonertinib |
|---|---|
| Date Designated: | 02/05/2024 |
| Orphan Designation: | Treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
ArriVent Biopharma, Inc. 18 Campus Blvd, Suite 100 Newtown Square, Pennsylvania 19073 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







